Pivotal Study of SonoClear® System Accepted for Presentation at EANS 2026 Congress

Presentation of Pivotal Study Findings on SonoClear® System

In an important development for the field of neurosurgery, findings from a pivotal multicenter trial investigating the SonoClear® System have been selected for an oral presentation at the upcoming European Association of Neurosurgical Societies (EANS) 2026 Annual Congress. This prestigious event is set to take place from September 30 to October 4, in Hamburg, Germany. The presentation will focus on enhancing intraoperative ultrasound imaging during glioma surgeries, which is vital for precise surgical outcomes.

Background of the Study

The SonoClear® System utilizes an innovative acoustic coupling fluid that aims to improve the clarity of ultrasound images during brain tumor resections. Intraoperative ultrasound has become an essential tool in neurosurgery, particularly in differentiating tumor margins from healthy brain tissue. However, one of the primary challenges neurosurgeons face is the occurrence of artifacts that can obscure critical visual information, especially at the end of tumor removal.

Francesco DiMeco, Professor of Neurosurgery at the University of Milan and director of the Department of Neurological Surgery at the Istituto Nazionale Neurologico Carlo Besta, will present the abstract titled "An Acoustic Coupling Fluid Improves Intraoperative Ultrasound Image Quality During Glioma Surgery Results of a Pivotal Multicenter Study". Dr. DiMeco, known for his extensive work with within neuro-oncological surgery, highlights the importance of overcoming these limitations to improve outcomes for patients.

The Findings

The multicenter study evaluated the efficacy of the SonoClear® System in alleviating the challenges posed by ultrasound imaging in glioma surgeries. The results indicate that the use of the acoustic coupling fluid significantly reduces interference caused by conventional irrigation fluids, leading to clearer images and improved decision-making capabilities for surgeons. This breakthrough could ultimately enhance the accuracy of tumor resections, which is crucial in increasing patient safety and surgical success rates.

Dr. DiMeco expressed his anticipation for sharing these significant findings with the neurosurgical community at EANS, underscoring the potential implications the study has for the future of neurosurgery.

Implications for Neurosurgery

Enhanced imaging during surgical procedures can translate into better operational decision-making. By overcoming the limitations of traditional ultrasound methods, the SonoClear® System is poised to lead to better surgical outcomes—including improved survival rates and reduced recurrence of tumors. In the U.S. alone, there are approximately 84,000 new cases of primary brain tumor diagnoses each year, a figure that extends further within the EU region. Thus, the implications of this study are vast, addressing a significant clinical gap in brain tumor surgeries.

Peter Balmforth, CEO of SonoClear, emphasized that the inclusion of their study at the EANS Congress represents a pivotal milestone for their program. It showcases growing clinical interest in refining intraoperative tools that directly benefit brain surgeries. As SonoClear continues to prepare for market introduction, they are dedicated to establishing broad clinical adoption following regulatory approvals.

About SonoClear® System

The SonoClear® System is distinctively designed to be sterile and biocompatible, matching the acoustic properties of brain tissue closely, which addresses the visual noise generated by conventional fluids. This innovative approach holds promise for neurosurgeons demanding accurate intraoperative imaging while performing complex brain surgeries. Currently, the system has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA), paving the way for future commercialization and widespread use.

While the future remains bright for the SonoClear® System, its successful integration into clinical practice will ultimately depend on the results of ongoing studies and the broader adoption of this technology in operating rooms worldwide. As the medical community prepares for the EANS 2026 congress, it will be an exciting opportunity to witness advancements that may redefine standard practices in neurosurgery, improve patient outcomes, and enhance overall quality of care.